Premium
De novo leukocyte chemotactic factor 2 amyloidosis in a pediatric renal allograft, 15 years post‐transplant
Author(s) -
Shamir Eliah R.,
Lee Marsha M.,
Walavalkar Vighnesh
Publication year - 2019
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.13371
Subject(s) - medicine , amyloidosis , renal transplant , chemotaxis , immunology , kidney transplantation , transplantation , pathology , receptor
Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a recently described form of systemic amyloidosis, which most commonly affects the kidney and liver. The LECT2 protein is produced during inflammatory processes, but its precise function in renal diseases in unclear. ALECT2, however, is known to be a relatively common form of renal amyloidosis, after amyloid light chain and serum amyloid A types and is most often seen in patients of Hispanic ethnicity. ALECT2 can occur de novo or as recurrent disease in kidney transplants. We present the first case, to our knowledge, of de novo ALECT2 in a pediatric kidney transplant patient, 15 years post‐transplant.